High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study

BRL-201 - BRL Medicine

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma

https://jitc.bmj.com/content/11/Suppl_1/A782

Biao Zheng1; YongXian Hu2; Jiqin Zhang1; Mingming Zhang3; Wei Li1; Wenjun Wu2; Jiazhen Cui2; Guoqing Wei3; Bing Du1; Mingyao Liu1; He Huang2

Sep 27, 2023